VBI Vaccines Inc (NASDAQ:VBIV)

1.87
Delayed Data
As of Jan 18
 -0.18 / -8.78%
Today’s Change
1.86
Today|||52-Week Range
4.83
-20.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$526.2M

Company Description

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Contact Information

VBI Vaccines, Inc.
222 3rd Street
Cambridge Massachusetts 02142
P:(617) 830-3031
Investor Relations:
16178303031124

Employees

Shareholders

Other institutional34.05%
Individual stakeholders26.34%
Mutual fund holders13.46%

Top Executives

Jeff BaxterPresident, Chief Executive Officer & Director
Christopher McNultyCFO, Director & Head-Business Development
Francisco Diaz-MitomaChief Medical Officer
David Evander AndersonChief Scientific Officer
T. Adam BuckleyVice President-Business Development